Preclinical in vivo data show that BRAF inhibitors do not impair lymphocyte viability, proliferation, or cytokine production at therapeutic concentrations, nor do they negatively impact serum cytokine levels or leukocyte counts in melanoma patients [63]. Here, BRAF is linked to melanoma.